Fearing that unscrupulous use may hijack this promising field, stakeholders are racing to regulate its applications. Are they swift enough?
“We don’t do clinical trials, we provide commercial stem-cell therapy,” says an executive of a Pune-based company on the phone when we inquire about participating in one to avail the treatment that its website boldly speaks of. “If you can’t come in person, send us your case study in email and we’ll advise you how many infusions of stem cells your patient would require,” he suggests.
The company’s website says it has provided 1,000 infusions to patients and is a ‘leader’ in stem-cells ‘therapy’. The so-called therapy costs upwards of Rs 2-3 lakh, the executive discloses on persuasion.
This Pune clinic is only one among the many that peddle the unproven stem-cell therapy. They are supposed to enrol patients under a proper clinical trial; instead they get by with merely adding the word ‘experimental’ to their offerings. You won’t find these clinics on the clinical trial registry of the Indian Council of Medical Research (ICMR), where they must enlist.
Now, contrast this liberally-delivered, unregulated treatment with what Stempeutics Research in Bangalore is trying to do. For seven years, the startup, promoted by the Manipal Group and led by chief executive BN Manohar, has been at the bench studying stem cells in its labs in India and Malaysia. With a series of clinical trials, government approvals, 24 patents, 41 journal publications and Rs 125 crore in investment, the company is finally close to launching one of its three—the least regulated one at that—stem cells-based products in 2013.
These two starkly opposite sides of how this new field of regenerative medicine is developing in India point to two problems that could derail the entire thing:
1. Regulatory hurdles that hit the growth of a nascent industry: The science behind it is advancing rapidly and the medical and commercial prospects are so promising that experts fear the regulatory gaps and delays are hurting the level playing field for entrepreneurs and investors who are fleeing to countries like Malaysia and Singapore. (While it takes just 60-90 days to get regulatory clearances in Malaysia, it may take 12-18 months in India.)
Of these, the CLI study is under fast track as the government is also keen to bring such a product to the market. “It’s an open label study so we can see the outcome; I can tell you that we have terrific results,” says Manohar. The final phase of most of these studies will be completed in 2013 and by end 2014 or early 2015, Stempeutics plans to roll out its products.
Srivastava says the question to ask is: Have these claimed successes been medically tested by independent physicians? “Personal testimonies are not scientific data and this distinction needs to be made when reporting these stories,” he says. (Some clinics, like Geeta Shroff’s NuTech Mediworld in Delhi, are beginning to understand this read end part of the story.
“To provide a path for progress with clinical stem-cells research in India during this period when the regulatory agency develops expertise and capacity and single path gets established, the ICMR and DBT, which have funded most of the academic clinical studies, have developed alternate paths for their review and approval based on the existing guidelines,” says Srivastava. The privately sponsored studies also follow a similar path through the DCGI and ICMR.
(This story appears in the 22 February, 2013 issue of Forbes India. To visit our Archives, click here.)